ALIBABA-GROUP
11.6.2019 06:02:07 CEST | Business Wire | Press release
Alibaba A.I. Labs, an AI research division of Alibaba Group, today announced at CES Asia partnerships with auto brands, including Audi, Renault and Honda to drive a smart mobility initiative in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005833/en/
Tmall Genie Auto, an Artificial Intelligence solution developed by Alibaba A.I. Labs, will be integrated into the automakers’ specific internet cars in China.
Owners of the three auto brands’ specific-model vehicles equipped with Tmall Genie Auto will have access to a wide variety of voice-controlled information and services in the near future; these include identifying nearby attractions and restaurants, booking movie tickets, ordering to-go boxes, checking the status of package deliveries, reading children’s books and ordering items on Alibaba’s retail platform.
In addition, car owners with a Tmall Genie-compatible device at home would be able to monitor and control their smart-home devices from their cars in the near future, performing daily tasks such as running a status check on temperature and light, or turning on the heater and air conditioning at home.
“By providing AI technologies, including speech-recognition and Natural Language Processing, Tmall Genie Auto enables car users to access an extensive in-car infotainment portfolio by tapping into Alibaba’s rich content and service ecosystem,” said Miffy Chen, General Manager at Alibaba A.I. Labs . “We are thrilled to partner with global distinguished auto brands such as Audi, Renault and Honda. Together, we can greatly enhance our in-car services and make driving experience more intelligent and interconnected.”
“We aim to extend in-car voice assistant services according to the demands and needs of our Chinese customers,” said H.W. Vassen, Senior Director of Digitalization and NEV Development at Audi China . “To do so, one of our next steps is to intensity the cooperation with Alibaba Tmall Genie.”
Guillaume SICARD, Vice President of Sales and Marketing, Region China, Groupe Renault , commented: “The launch of the Renault City K-ZE Tmall Genie Edition allows consumers to experience a deeper connection between scenarios in their lives at home and their lives on the go. It is also a manifesto that DRAC and Tmall will continue to maintain profound cooperation on areas such as brand marketing, potential customer mining and sales network enablement, in order to achieve new breakthroughs.”
Hasegawa Yusuke, the Executive Vice President of Honda Motor (China) Investment Co., Ltd , said: “The world’s mobility industries are currently undergoing a major transformation. Our mobility and daily lives will finally enter into the era of Internet for Everything, Honda has been actively embracing the trend of electrification and ICVs, and accelerating the advancement of the third-generation Honda CONNECT system which includes the Smart AI function. We look forward to working with Alibaba A.I. Labs on creative initiatives by leveraging the AI technology and Alibaba’s diverse ecosystem services.”
During CES Asia, Alibaba’s B2C marketplace Tmall also announced its tie-up with Renault to roll out an electric car featuring Tmall’s iconic cat logo on the vehicle’s exterior design. The Renault City K-ZE genie edition, also integrated with Tmall Genie Auto, will be on sale in China later this year.
Tmall Genie is the bestselling smart speaker in China. Today it can control over 100 million devices from over 600 smart appliance brands, offering its Internet of Things ecosystem capabilities to various sectors and user environments from home, car, hotels to nursing homes.
Alibaba A.I. Labs spearheads consumer AI product development at Alibaba Group. Since the launch of Tmall Genie Auto solution last April, Alibaba A.I. Labs has also partnered with auto brands including BMW and Volvo Cars to provide intelligent and connected mobility experiences for consumers in China.
About Alibaba A.I. Labs
Alibaba A.I. Labs is dedicated to exploring the next-generation human-and-computer interaction and turning novel user experience into reality. The in-house R&D department focuses on the development of innovative AI applications across Alibaba’s commerce ecosystem and provides AI solutions to Alibaba’s clients and partners. With a world-class research team, Alibaba A.I. Labs focuses on both theoretical research and product commercialization in various areas, including speech recognition, natural language processing, voice print identification, deep learning, and computer vision. The Labs also focuses on developing AI products for consumers, including Tmall Genie, the first voice- controlled smart home assistant developed by the Labs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005833/en/
Contact:
Crystal Liu Alibaba Group +86 18578497650/+852 6378 5626 Crystal.liu@alibaba-inc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom